A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versusoriginator filgrastim for chemotherapy-induced neutropenia in breast cancer patients

Autor: Hegg, Roberto, Mattar, André, de Matos, João Nunes, Pedrini, José Luiz, Aleixo, Sabina Bandeira, Rocha, Roberto Odebrecht, Cramer, Renato Peixoto, van-Eyll-Rocha, Sylvie
Zdroj: Clinics; January 2016, Vol. 71 Issue: 10 p586-592, 7p
Abstrakt: To compare the efficacy and safety of two filgrastim formulations for controlling chemotherapy-induced neutropenia and to evaluate the non-inferiority of the test drug relative to the originator.
Databáze: Supplemental Index